Investors Purchase High Volume of Put Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Investors bought 48,643 put options on SELLAS on Monday, 19% above the average volume of 40,961.
  • The stock fell $0.33 to $7.53 during Monday’s trading. Its 52-week range is $1.39 to $15.88.
  • Analysts’ average rating is Hold, with a $10 price target; SELLAS reported quarterly EPS of -$0.05, in line with estimates.
  • MarketBeat previews top five stocks to own in December.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading on Monday. Investors purchased 48,643 put options on the company. This is an increase of 19% compared to the average volume of 40,961 put options.

Wall Street Analysts Forecast Growth

SLS has been the subject of several analyst reports. Alliance Global Partners reaffirmed a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $10.00.

Check Out Our Latest Research Report on SELLAS Life Sciences Group

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock traded down $0.33 during midday trading on Monday, reaching $7.53. The stock had a trading volume of 3,178,609 shares, compared to its average volume of 7,843,897. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $15.88. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -37.65 and a beta of 2.73. The firm's fifty day simple moving average is $11.03 and its two-hundred day simple moving average is $8.77.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock worth $27,000 after purchasing an additional 1,630 shares during the period. California State Teachers Retirement System grew its position in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after purchasing an additional 1,709 shares in the last quarter. Nykredit A S acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at approximately $27,000. Pictet Asset Management Holding SA increased its stake in SELLAS Life Sciences Group by 15.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 27,688 shares of the company's stock valued at $341,000 after buying an additional 3,704 shares during the period. Finally, Private Advisor Group LLC increased its stake in SELLAS Life Sciences Group by 36.0% in the 3rd quarter. Private Advisor Group LLC now owns 21,278 shares of the company's stock valued at $262,000 after buying an additional 5,628 shares during the period. Hedge funds and other institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines